1921
Volume 94, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

French Polynesia is considered to be moderately endemic for chronic hepatitis B virus infection, with an estimated 3% of the population having hepatitis B surface antigen (HBsAg). From 1990 to 1992, a 3-dose hepatitis B vaccination series was introduced into the routine infant immunization schedule in French Polynesia, including a birth dose (BD). In 2014, a nationally representative 2-stage cluster survey was undertaken to evaluate the impact of the vaccination program on HBsAg prevalence among school children (∼6 years of age) in Cours Préparatoire (CP). Documented vaccination data were reviewed for all eligible children; children with consent were tested for HBsAg with a rapid point-of-care test. In total, 1,660 students were identified; 1,567 (94%) had vaccination data for review and 1,196 (72%) participated in the serosurvey. Three-dose vaccination coverage was 98%, while timely BD coverage, defined as a dose administered within 24 hours of life, was 89%. Receipt of the second and third doses was often delayed, with 75% and 55% receiving a second and third dose within 1 month of the recommended age, respectively. No children tested positive for HBsAg. French Polynesia's vaccination program has achieved high coverage and an HBsAg seroprevalence of 0% (0–0.5%) among CP school children, but timeliness of vaccination could be improved.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0903
2016-06-01
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/6/1370.html?itemId=/content/journals/10.4269/ajtmh.15-0903&mimeType=html&fmt=ahah

References

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST, , 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 22122219.[Crossref]
  2. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS, , 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 13291339.[Crossref]
  3. Clements CJ, Baoping Y, Crouch A, Hipgrave D, Mansoor O, Nelson CB, Treleaven S, van Konkelenberg R, Wiersma S, , 2006. Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine 24: 19751982.[Crossref]
  4. Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S, , 2013. Hepatitis B control in the World Health Organization's Western Pacific Region: targets, strategies, status. Vaccine 31 (Suppl 9): J85J92.[Crossref]
  5. Regional Committee of the Western Pacific, 2013. Hepatitis B Control through Vaccination: Setting the Target. WPR/RC64.R5. Manila, Philippines: WHO Regional Office for the Western Pacific.
  6. World Health Organization, 2007. Western Pacific Regional Plan for Hepatitis B Control through Immunization. Manila, Philippines: WHO Regional Office for the Western Pacific.
  7. Boutin JP, Sainte Marie FF, Cartel JL, Cardines R, Girard M, Roux J, , 1990. Prevalence of hepatitis B virus infection in the Austral archipelago, French Polynesia: identification of transmission patterns for the formulation of immunization strategies. Trans R Soc Trop Med Hyg 84: 283287.[Crossref]
  8. Brindle RJ, Eglin RP, Parsons AJ, Hill AV, Selkon JB, , 1988. HTLV-1, HIV-1, hepatitis B and hepatitis delta in the Pacific and south-east Asia: a serological survey. Epidemiol Infect 100: 153156.[Crossref]
  9. Renou L, Ségalin J-M, , 2013. Evaluation de la Couverture Vaccinale des élèves scolarisés en Polynésie française, année scolaire 2011–2012. Tahiti, Polynésie Française: Direction de la Santé.
  10. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, Laras K, Corwin A, , 2000. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 62: 301309.
  11. Alere, 2011. Alere Determine HBsAg Package Insert. Available at: http://www.alere.com/en/home/product-details/determine-hbsag.html. Chiba, Japan: Alere.
  12. World Health Organization, 2001. Hepatitis B Surface Antigen Assays: Operational Characteristics (Phase 1). Report 1. Geneva, Switzerland: World Health Organization.
  13. Rubin D, Schenker N, , 1987. Logit-based interval estimation for binomial data using the Jeffrey's prior. Sociol Methodol 17: 131144.[Crossref]
  14. World Health Organization, 2013. Global Vaccine Action Plan, 2011–2020. Geneva, Switzerland: World Health Organization.
  15. WHO Regional Office of the Western Pacific, 2011. Western Pacific Country Health Information Profiles: 2011 Revision. Geneva, Switzerland: World Health Organization.
  16. Wallace AS, Sobel H, Ryman TK, Mantaring JB, 3rd Silvestre M, Thorley M, Ducusin J, Nyunt US, , 2012. Timing of hepatitis B vaccination and impact of non-simultaneous vaccination with DTP vaccine following introduction of a hepatitis B birth dose in the Philippines. J Public Health Policy 33: 368381.[Crossref]
  17. Clark A, Sanderson C, , 2009. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 373: 15431549.[Crossref]
  18. Hull BP, McIntyre PB, , 2006. Timeliness of childhood immunisation in Australia. Vaccine 24: 44034408.[Crossref]
  19. Zhou Y, Wang H, Zheng J, Zhu X, Xia W, Hipgrave DB, , 2009. Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People's Republic of China. Am J Trop Med Hyg 81: 869874.[Crossref]
  20. Bielicki JA, Achermann R, Berger C, , 2012. Timing of measles immunization and effective population vaccine coverage. Pediatrics 130: e600e606.[Crossref]
  21. Luman ET, Barker LE, Shaw KM, McCauley MM, Buehler JW, Pickering LK, , 2005. Timeliness of childhood vaccinations in the United States: days undervaccinated and number of vaccines delayed. JAMA 293: 12041211.[Crossref]
  22. Dominguez SR, Parrott JS, Lauderdale DS, Daum RS, , 2004. On-time immunization rates among children who enter Chicago public schools. Pediatrics 114: e741e747.[Crossref]
  23. Heininger U, Zuberbuhler M, , 2006. Immunization rates and timely administration in pre-school and school-aged children. Eur J Pediatr 165: 124129.[Crossref]
  24. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M, , 2015. National, state, and selected local area vaccination coverage among children aged 19–35 months—United States, 2014. MMWR 64: 889896.
  25. World Health Organization, 2010. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine 28: 589590.[Crossref]
  26. Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, Kandun N, Marschner IC, Maynard JE, , 1995. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. J Infect Dis 171: 290296.[Crossref]
  27. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ, Advisory Committee on Immunization Practices; , 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54: 131.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0903
Loading
/content/journals/10.4269/ajtmh.15-0903
Loading

Data & Media loading...

  • Received : 15 Dec 2015
  • Accepted : 12 Feb 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error